Sartorius Group Reports Preliminary FY25 Profit Increase

Sartorius AG (SRTGF, SART.DE) reported a preliminary net profit increase for fiscal year 2025, which ended December 31, 2025, driven by strong demand in its lab and bioprocessing segments. The German life sciences company cited robust sales growth and operational efficiency as key contributors to the improved earnings. The company expects net profit to rise approximately 12% year-over-year, reaching around €850 million. Revenue is projected to grow roughly 9% at constant currencies, totaling about €4.7 billion. Sartorius also confirmed its full-year guidance for underlying EBITDA margin to remain stable at approximately 28%. Final audited results are scheduled for release on March 12, 2026.